Need for a paradigm shift: The importance of risk factor reduction therapy in treating patients with cardiovascular disease

American Journal of Cardiology

Volumn 82, Issue 10 B, 1998, Pages

  Smith Jr , Sidney C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIET; EXERCISE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; HYPERCHOLESTEROLEMIA; LOW FAT DIET; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DIET, FAT-RESTRICTED; EXERCISE; HUMANS; RISK FACTORS; SMOKING CESSATION;

EID: 0345059426     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Heart and Stroke Facts 1997 (Statistical Supplement). Dallas, TX: American Heart Association; 1997.
2. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
3. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W. Jr, Rosenfeld M.E., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association . Circulation. 92:1995;1355-1374.
4. Fuster V., Lewis A. Connor Memorial Lecture mechanisms leading to myocardial infarction: insights from studies of vascular biology . Circulation. 90:1994;2126-2146.
5. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
6. Muller J.E., Abela G.S., Nesto R.W., Tofler G.H. Triggers, acute risk factors and vulnerable plaques the lexicon of a new frontier . J Am Coll Cardiol. 23:1994;809-813.
7. Levine G.N., Keaney J.F. Jr, Vita J.A. Cholesterol reduction in cardiovascular disease clinical benefits and possible mechanisms . N Engl J Med. 332:1995;512-521.
8. Philbin E.F., Pearson T.A. How does lipid-lowering therapy rapidly reduce ischemic events? J Myocard Ischemia. 6:1994;13-18.
9. Pitt B., Mancini G.B., Ellis S.G., Rosman H.S., Park J.S., McGovern M.E. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis and clinical events. PLAC I investigation. J Am Coll Cardiol. 26:1995;1133-1139.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
11. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
12. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
13. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
14. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J. Jr, Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 327:1992;669-677.
15. Lonn E.M., Yusuf S., Jha P., Montague T.J., Teo K.K., Benedict C.R., Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
16. Brown M.S., Goldstein J.L. Heart attacks gone with the century? (Editorial.) Science. 272:1996;629.
17. Cohen M.V., Byrne M.J., Levine B., Gutowski T., Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary disease. Circulation. 83:1991;1294-1304.
18. Smith S.C. Jr, Blair S.N., Criqui M.H., Fletcher G.F., Fuster V., Gersh B.J., Goto A.M., Gould K.L., Greenland P., Grundy S.M. Preventing heart attack and death in patients with coronary disease. Consensus panel statement. Circulation. 92:1995;2-4.
19. Parish S., Collins R., Peto R., Youngman L., Barton J., Jayne K., Clarke R., Appleby P., Lyon V., Cederholm-Williams S. Cigarette smoking tar yields and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. Br J Med. 31:1995;471-477.
20. Peto R. Mortality from Smoking in Developed Countries, 1950-2000. Indirect estimates from national vital statistics. New York, NY: Oxford University Press; 1994.
21. Bartecchi C.E., MacKenzie T.D., Schrier R.W. The human costs of tobacco use (1). N Engl J Med. 330:1994;907-912.
22. MacKenzie T.D., Bartecchi C.E., Schrier R.W. The human costs of tobacco use (2). N Engl J Med. 330:1994;975-980.
23. Garcia-Dorado D., Theroux P., Tornos P., Sambola A., Oliveras J., Santos M., Soler J. Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation. 92:1995;1743-1748.
24. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction an overview of the randomized trials . Prog Cardiovas Dis. 27:1985;335-371.
25. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., Platt R. Discontinuation of antihyperlipidemic drugs do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 332:1995;1125-1131.
26. Patient Compliance: Lipid Lowering Agents TOP Study. Merck & Co. Inc.; 1992.
27. Gillum R.F., Neutra R.R., Stason W.B., Solomon H.S. Determinants of dropout rate among hypertensive patients in an urban clinic. J Community Health. 5:1979;94-100.
28. Wirebaugh S.R., Whitney E.J. Long-term compliance with lipid-lowering therapy. Pharmacol Ther. 18:1993;559-571.
29. DeBusk R.F., Miller N.H., Superko H.R., Dennis C.A., Thomas R.J., Lew H.T., Berger W.E. III, Heller R.S., Rompf J., Gee D. A case-managerial system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 120:1994;721-729.
30. The American Heart Association Bulletin November 1925:1(2).